Tm3 Therapeutics LLC is categorized under Biochemical Laboratories in Hayward, CA .
Tm3 Therapeutics LLC was established in 0, and today employs 1 to 4, earning Unknown per year. This is a Biochemical Laboratories business, which does work in the B2B market, and is classified as a Biochemical Laboratories, under code number 5417114 by the NAICS.
If you are seeking more information, feel free to contact Hassibullah Akeefe, Other at the company’s single location by writing to 3521 Investment Boulevard # 1, Hayward, California CA 94545 or by phoning (510) 266-0087. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Tm3 Therapeutics LLC |
| Contact Person: | Hassibullah Akeefe, Other |
| Address: | 3521 Investment Boulevard # 1, Hayward, California 94545 |
| Phone Number: | (510) 266-0087 |
| Website Address: | tm3therapeutics.com |
| Annual Revenue (USD): | Unknown |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biochemical Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 5417114 |
| Share This Business: |
Tm3 Therapeutics LLC was started in 0 to provide professional Biochemical Laboratories under the SIC code 8731 and NAICS code 5417114. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Hassibullah Akeefe, Other for inquiries that concern Tm3 Therapeutics LLC by calling the company number (510) 266-0087, as your correspondence is most welcome. Additionally, the physical location of the single location of Tm3 Therapeutics LLC can be found at the coordinates 37.62475,-122.12085 as well as the street address 3521 Investment Boulevard # 1 in Hayward, California 94545.
For its online presence, you may visit Tm3 Therapeutics LLC’s website at tm3therapeutics.com and engage with its social media outlets through on Twitter and on Facebook.